---
figid: PMC6745708__nihms-1049964-f0001
figtitle: The RTK signaling network and nodes of therapeutic blockade
organisms:
- NA
pmcid: PMC6745708
filename: nihms-1049964-f0001.jpg
figlink: /pmc/articles/PMC6745708/figure/F1/
number: F1
caption: 'Activation of RTKs can result in signaling via two pathways: PI3/AKT and
  RAS/RAF/MEK/ERK. PI3K/AKT signaling induces cell survival, increases protein synthesis,
  activates glucose metabolism, and decreases apoptosis. RAS/RAF/MEK/ERK increases
  cellular proliferation, angiogenesis, migration, and differentiation by activating
  transcriptional factors in a cascade. Each ligand binds to RTK and transfers the
  extracellular signal to the cytosol and then, ultimately, to the nucleus. Targeted
  therapy using monoclonal antibody (-MAB or -IB) or TKI can block the extracellular
  signals which enter the cell through the RTK pathway.'
papertitle: Protein Tyrosine signaling and its potential therapeutic implications
  in carcinogenesis.
reftext: Mihwa Kim, et al. Curr Pharm Des. 2017 Nov 16;23(29):4226-4246.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9542562
figid_alias: PMC6745708__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6745708__F1
ndex: 9b26cef8-deb5-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6745708__nihms-1049964-f0001.html
  '@type': Dataset
  description: 'Activation of RTKs can result in signaling via two pathways: PI3/AKT
    and RAS/RAF/MEK/ERK. PI3K/AKT signaling induces cell survival, increases protein
    synthesis, activates glucose metabolism, and decreases apoptosis. RAS/RAF/MEK/ERK
    increases cellular proliferation, angiogenesis, migration, and differentiation
    by activating transcriptional factors in a cascade. Each ligand binds to RTK and
    transfers the extracellular signal to the cytosol and then, ultimately, to the
    nucleus. Targeted therapy using monoclonal antibody (-MAB or -IB) or TKI can block
    the extracellular signals which enter the cell through the RTK pathway.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IGF1
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - HGF
  - IL6
  - SOS1
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - GDNF
  - EGF
  - EGFR
  - KDR
  - FLT1
  - FLT4
  - ERBB2
  - RET
  - ALK
  - IGF1R
  - XYLT2
  - SOS2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - AKT1
  - AKT2
  - AKT3
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MTOR
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - Vandetanib
  - Pazopanib
  - AZD6244
  - AZD8055
  - GSK2118436
  - tyrosine
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
